Search

Your search keyword '"Portelius, Erik"' showing total 828 results

Search Constraints

Start Over You searched for: Author "Portelius, Erik" Remove constraint Author: "Portelius, Erik"
828 results on '"Portelius, Erik"'

Search Results

3. Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides

5. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain

7. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.

8. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

9. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

14. Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology

15. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy

18. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

19. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease

23. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg

24. Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain

25. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology

26. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

28. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders

32. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21

33. Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70

35. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders.

36. Specific mutations in the cholesterol-binding site of APP alter its processing and favor the production of shorter, less toxic Aβ peptides.

38. Cerebral organoids: in vitro model for brain development and neurodegeneration

39. Additional file 1 of Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease

42. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

44. γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing

45. Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls

Catalog

Books, media, physical & digital resources